SMS Chatbot Support for Gastrointestinal Cancer

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Abramson Cancer Center of the University of Pennsylvania

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial focuses on using capecitabine, an oral chemotherapy drug, for cancer patients who manage their treatment at home. The goal is to help these patients take their medication correctly and manage side effects better. Capecitabine works by stopping cancer cells from growing and spreading and is used in the treatment of various cancers, including advanced breast and colorectal cancer.

Research Team

Eligibility Criteria

This trial is for patients with gastrointestinal cancers who are taking oral chemotherapy, specifically capecitabine alone or in combination with other treatments like oxaliplatin, temozolomide, radiation therapy, or mitomycin.

Inclusion Criteria

I am over 18 and being treated for GI cancer with specific medications.

Treatment Details

Interventions

'Penny' via Memora Platform (Behavioural Intervention)

Trial Overview'Penny' is a chatbot delivered via the Memora Platform designed to help these patients manage their medication schedules and side effects. The study aims to improve adherence to complex oral chemotherapy regimens and better handle toxicity by providing remote guidance and monitoring.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Penny, a SMS Text-based chatbot interventionExperimental Treatment1 Intervention

This is a single arm study. All recruited patients will be entered on the Penny SMS Text-based chatbot intervention.